Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462837 · ClinicalTrials.gov registry record · Phase 2
Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement
A Phase 2 study, sponsored by Southern Illinois University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02462837: Clinical Trial Phase 2 study, sponsored by Southern Illinois University.
NCT02462837 is a Phase 2 study that was terminated before completion, run by Southern Illinois University. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02462837, a Phase 2 study, was terminated before completion, sponsored by Southern Illinois University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The objective of this pilot study is to assess whether Myrbetriq™ will improve post-operative ureteral pain and discomfort, reduce bladder storage symptoms and increase quality of life following ureteral stenting.
Primary Outcome
Incontinence symptom severity index is a self-assessment instrument for voiding symptom severity. It assesses 8 symptom domains: emptying, urgency, urge incontinence, nocturia, daytime frequency, stress incontinence, leakage with physical activity, and pad use. absent/mild (0-6), moderate (7-16), severe (\>16).
Interventions
- DRUG Placebo
- DRUG Mirabegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2015-05 |
| Est. Completion | 2019-01-30 |
| Phase | Phase 2 |
Why NCT02462837 stopped before completion
NCT02462837 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02462837 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02462837 about?
NCT02462837 is a clinical study titled "Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement". The objective of this pilot study is to assess whether Myrbetriq™ will improve post-operative ureteral pain and discomfort, reduce bladder storage symptoms and increase quality of life following ureteral stenting.
What is the current status of trial NCT02462837?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2015-05. Estimated completion is 2019-01-30.
What interventions are being tested in trial NCT02462837?
The interventions under investigation include: Placebo (DRUG), Mirabegron (DRUG).
Who is sponsoring clinical trial NCT02462837?
This trial is sponsored by Southern Illinois University, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02462837's enrollment target sits among peer trials
11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia